Binding Antibody Component

Antigen specific antibody responses using customizable antigen-specific binding assays are provided by the CFAR Immunology core under GCLP-compliant conditions. These assays can be used to profile global changes in isotype and subclass responses to infection or vaccination. HIV, TB, and SIV specific assays are currently available. Antibody assays include a binding antibody multiplex assay (BAMA), Pharmacokinetic (PK) concentrations, avidity index assay (BAMA-AI) and antibody peptide microarray, virion capture and phagocytosis. The Binding Antibody Multiplex Assay (BAMA) has multiplex capability to profile antibody isotypes and subclasses (IgG1-4, dIgA, SCIgA, IgA1-2, IgM) for multiple antigens simultaneously (e.g. 50-100 different proteins/epitopes). We have developed standardized, qualified, and validated assays for multiple bNAbs in the product development pipeline, including parent and LS mAbs, in HIV-1 seronegative and seropositive serum (infants-adults). For the antigen specific assays, avidity measures can profile the strength of interactions using specific peptides and a sodium-citrate step. Peptide microarrays are available for HIV and SIV antigens (with potential for TB epitopes). HIV virion capture assays can distinguish the capacity of different antibody specificities to recognize infectious and noninfectious virus particles. HIV-1 phagocytosis assays are employed to test the ability of vaccine or infection induced antibodies to engage FcR on primary monocyte/macrophages and neutrophils in addition to recognition of virus particles.